Peter, I guess we'll see some action today... might not be a good day for bio-tech...
Regards, Frank P.
Merck Revenues Doubted
NEW YORK (AP) - More than $12 billion in revenue reported by Merck & Co. was never collected by the drug giant's pharmacy-benefits unit, The Wall Street Journal reported.
Merck counted patients' co-payments to pharmacies as revenue generated by its Medco unit, which manages pharmacy-benefit programs for businesses and health insurance companies, the newspaper reported Monday.
Medco, however, did not actually receive those co-payments, which totaled almost 10 percent of its overall reported revenue in 1999, 2000 and 2001.
The company told The Wall Street Journal that its accounting practice meet generally accepted standards and that it also counts co-payment amounts as expenses, meaning the practice does not effect its net income.
The exact amount of reported but not collected revenue — $12.4 billion — was reported in a Friday filing by Merck with the Securities and Exchange Commission ( news - web sites).
The accounting practice itself was reported in an April SEC filing and publicized two weeks ago by the Journal. Merck stock dropped 5 percent, to a five-year low, after the article was published.
There is no indication that the SEC has taken issue with how Merck treats co-payment amounts, the newspaper reported.
The revenue in question is the co-payment paid by consumers with a prescription drug card to their retail pharmacy to cover their portion of the cost of a drug under an insurance plan. The pharmacy keeps the entire amount of the co-payment.
Merck, the world's third-largest drug maker, hurt by slumping profits and a slowdown in its drug pipeline, has been under pressure to spin off its Merck-Medco subsidiary.
With $29.1 billion in revenues last year, the unit generated over half of its parent's overall sales. But Medco's razor-thin profit margin, barely 1 percent, hurt Merck's bottom line.
News 
Market Data 
Discover 
AI
